MedTrace Logo

International Leukemia Target Board

NCT05270096 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-01-09

No results posted yet for this study

Summary

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.

The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level.

As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.

Conditions

  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy

Interventions

OTHER

Advice

non-interventional study

Sponsors & Collaborators

  • Princess Maxima Center for Pediatric Oncology

    lead OTHER

Principal Investigators

  • Michel Zwaan, Prof. dr. · Princess Maxima Center for Pediatric Oncology

  • Monique den Boer, Prof. dr. · Princess Maxima Center for Pediatric Oncology

Eligibility

Min Age
0 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2030-07-01
Completion
2032-06-01

Countries

  • Belgium
  • Denmark
  • Hungary
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05270096 on ClinicalTrials.gov